A detailed history of Raymond James & Associates transactions in Insmed Inc stock. As of the latest transaction made, Raymond James & Associates holds 76,232 shares of INSM stock, worth $5.58 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
76,232
Previous 64,944 17.38%
Holding current value
$5.58 Million
Previous $4.35 Million 27.88%
% of portfolio
0.0%
Previous 0.0%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

BUY
$62.0 - $79.01 $699,856 - $891,864
11,288 Added 17.38%
76,232 $5.56 Million
Q2 2024

Jul 19, 2024

BUY
$22.0 - $69.71 $64,746 - $205,156
2,943 Added 4.75%
64,944 $4.35 Million
Q1 2024

Apr 22, 2024

BUY
$25.72 - $29.94 $537,162 - $625,296
20,885 Added 50.8%
62,001 $1.68 Million
Q4 2023

Jan 16, 2024

SELL
$23.42 - $31.74 $72,555 - $98,330
-3,098 Reduced 7.01%
41,116 $1.27 Million
Q3 2023

Oct 24, 2023

BUY
$19.86 - $26.93 $249,699 - $338,590
12,573 Added 39.74%
44,214 $1.12 Million
Q2 2023

Jul 25, 2023

SELL
$16.44 - $21.1 $11,376 - $14,601
-692 Reduced 2.14%
31,641 $667,000
Q1 2023

Apr 14, 2023

BUY
$16.26 - $21.73 $73,852 - $98,697
4,542 Added 16.34%
32,333 $551,000
Q4 2022

Feb 08, 2023

BUY
$16.98 - $23.15 $104,104 - $141,932
6,131 Added 28.31%
27,791 $555,000
Q3 2022

Oct 25, 2022

BUY
$20.88 - $28.21 $17,748 - $23,978
850 Added 4.08%
21,660 $467,000
Q2 2022

Aug 12, 2022

SELL
$17.07 - $25.71 $1,314 - $1,979
-77 Reduced 0.37%
20,810 $410,000
Q1 2022

May 11, 2022

SELL
$20.42 - $28.13 $5,799 - $7,988
-284 Reduced 1.34%
20,887 $491,000
Q4 2021

Feb 08, 2022

SELL
$25.89 - $33.45 $20,478 - $26,458
-791 Reduced 3.6%
21,171 $577,000
Q3 2021

Nov 02, 2021

SELL
$22.46 - $29.47 $24,077 - $31,591
-1,072 Reduced 4.65%
21,962 $605,000
Q2 2021

Aug 11, 2021

BUY
$24.17 - $36.01 $17,934 - $26,719
742 Added 3.33%
23,034 $656,000
Q1 2021

May 14, 2021

SELL
$32.28 - $44.3 $18,593 - $25,516
-576 Reduced 2.52%
22,292 $759,000
Q4 2020

Feb 12, 2021

SELL
$31.45 - $40.54 $20,473 - $26,391
-651 Reduced 2.77%
22,868 $761,000
Q3 2020

Nov 04, 2020

BUY
$26.0 - $34.5 $13,494 - $17,905
519 Added 2.26%
23,519 $756,000
Q2 2020

Jul 28, 2020

BUY
$14.11 - $29.42 $82,811 - $172,665
5,869 Added 34.26%
23,000 $633,000
Q1 2020

Apr 21, 2020

SELL
$13.63 - $33.98 $2.43 Million - $6.07 Million
-178,518 Reduced 91.24%
17,131 $275,000
Q4 2019

Feb 12, 2020

BUY
$16.12 - $24.98 $296,914 - $460,106
18,419 Added 10.39%
195,649 $4.67 Million
Q3 2019

Nov 07, 2019

BUY
$15.49 - $25.78 $541,112 - $900,572
34,933 Added 24.55%
177,230 $3.13 Million
Q2 2019

Aug 06, 2019

BUY
$23.0 - $32.19 $919,448 - $1.29 Million
39,976 Added 39.07%
142,297 $3.64 Million
Q1 2019

May 06, 2019

BUY
$13.91 - $31.15 $619,885 - $1.39 Million
44,564 Added 77.16%
102,321 $2.97 Million
Q4 2018

Feb 11, 2019

BUY
$11.6 - $18.7 $338,140 - $545,105
29,150 Added 101.9%
57,757 $758,000
Q3 2018

Nov 14, 2018

BUY
$18.95 - $28.08 $542,102 - $803,284
28,607 New
28,607 $578,000

Others Institutions Holding INSM

About INSMED Inc


  • Ticker INSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,476,992
  • Market Cap $9.91B
  • Description
  • Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...
More about INSM
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.